Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M29,529Revenue (TTM) $M22,723Net Margin (%)1.5Altman Z-Score0.8
Enterprise Value $M68,963EPS (TTM) $0.0Operating Margin %8.3Piotroski F-Score3
P/E(ttm)2,898Beneish M-Score-2.3Pre-tax Margin (%)2.8Higher ROA y-yN
Price/Book1.010-y EBITDA Growth Rate %6.8Quick Ratio0.6Cash flow > EarningsY
Price/Sales1.35-y EBITDA Growth Rate %-4.8Current Ratio0.9Lower Leverage y-yN
Price/Free Cash Flow8.4y-y EBITDA Growth Rate %-41.4ROA % (ttm)0.4Higher Current Ratio y-yN
Dividend Yield %4.7PEG--ROE % (ttm)0.2Less Shares Outstanding y-yN
Payout Ratio %6,800Shares Outstanding M1,016ROIC % (ttm)2.7Gross Margin Increase y-yN

Gurus Latest Trades with TEVA

Number of guru portfolios checked: 68.
Ticker Guru Date Action
Impact Price Range
(Average)*
Current Price Change from Average Comment Current Shares

TEVA is held by these investors:



TEVA: Insider Buys/Sells

Click Here for All Insider Trades.

No Insider Trades Found!

Quarterly/Annual Reports about TEVA:

    News about TEVA:

    Articles On GuruFocus.com
    Francis Chou Buys Pharmaceutical Stocks, Including Valeant May 17 2017 
    Stocks That Fell to 3-Year Lows in the Week of April 14 Apr 22 2017 
    What Will Make Man Smarter? Apr 10 2017 
    Risk-Reward With Teva Pharmaceutical Mar 27 2017 
    23 Questions With the Founder of WayUndervalued.com Mar 26 2017 
    Valeant: It's Not a Game of Chess Part I Mar 16 2017 
    Who Is Winning the Fight Against Opioid Abuse? Feb 27 2017 
    David Tepper Invests Heavily in Pharma in 4th Quarter Feb 16 2017 
    Beaten-Down Valuation and a 3% Dividend Yield Feb 07 2017 
    Naltrexone Showing More Potential in Drug Addiction Treatment Market Feb 05 2017 

    More From Other Websites
    Teva Reaches New Lows – Will It Bottom Out? May 23 2017
    It's Easy To Be Skeptical Of Mylan, But Don't Ignore This Pending PDUFA Date May 22 2017
    3 Drug Stocks Billionaire Money Managers Dumped Big-Time in the First Quarter May 22 2017
    Valeant Pharmaceuticals: Intrigued…Really? May 19 2017
    Valeant (VRX) Decides to Extend Stay on Xifaxan's ANDA May 19 2017
    Vetr Issues Strong Buy As Teva Trends Down May 19 2017
    Teva Pharmaceutical Leaning Towards Foreigner as New CEO May 18 2017
    Teva Pharmaceutical's search committee recommends foreign CEO: report May 18 2017
    Teva Showcases Asthma Research at the 2017 American Thoracic Society (ATS) International Conference May 17 2017
    Teva to Present Data for Deutetrabenazine in Tardive Dyskinesia at the American Psychiatric... May 17 2017
    Teva (TEVA) Launches Glumetza Generic, Inks Deal with Otsuka May 16 2017
    John Paulson Takes A Shine To Telecom May 15 2017
    Teva Announces Launch of Generic Glumetza® in the United States May 15 2017
    Otsuka and Teva Sign Licensing Agreement for Japan on Prophylactic Migraine Drug Candidate... May 15 2017
    Biostime International Holdings Limited -- Moody's: Biostime's ratings unaffected by disclosure of... May 15 2017
    Can Teva Hold Its Own In Bringing Migraine Drugs To Market? May 12 2017
    Here's How Much Teva Pharmaceutical Could Net From the Sale of Non-Core Assets May 12 2017
    Today's Research Reports on Stocks to Watch: Teva Pharmaceuticals and Merck & Co. May 12 2017
    Teva (TEVA) Q1 Earnings In Line, Sales Lag as Copaxone Falls May 12 2017

    Add Notes, Comments

    If you want to ask a question or report a bug, please create a support ticket.
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

    GF Chat